ProBioGen
ProBioGen is a Berlin-based specialist for developing and manufacturing biopharmaceutical active ingredients, viral vectors and vaccines with applying proprietary technologies to improve product quality and features.Combining both state-of-the-art development services, based on ProBioGen's CHO.RiGHT® expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties. Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with GMP standards (EMA/FDA).ProBioGen has been operational for more than 30 years. At four locations in Berlin, 300 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work. ProBioGen's growth strategy is driven by the expansion of the service value chain through organic growth and potential acquisition. Diversification is a complement driver, while the focus is strict on enabling the development of biopharmaceuticals for tomorrow.Content by ProBioGen
| 2 min read
ProBioGen will apply its CHO.RiGHT platform and GlymaxX technology to support Spica’s first clinical candidate, the anti-CD163 antibody ST101.
| 1 min read
ProBioGen announced the commercial launch of Ziihera®, a bispecific antibody for HER2-positive biliary tract cancer developed with its GlymaxX® technology.
Page 1 of 1 - 2 Total Items
